Visoluten
The Khavinson retinal bioregulator preparation, marketed in Russia for age-related retinal change including macular degeneration support. Evidence base is Russian-language Khavinson-group studies. Not FDA- or EMA-approved.
A retinal-tissue-derived short peptide preparation in the Khavinson cytomedine series. Marketed in Russia for age-related retinal decline. Evidence for efficacy in age-related macular degeneration or diabetic retinopathy is limited to Russian-language studies from the Khavinson group and affiliated ophthalmology centers, with minimal methodological rigor by Western standards.
Mechanism of action
Proposed tissue-specific transcriptional modulation in retinal cells under the Khavinson bioregulator framework. Not mechanistically characterized at molecular-target resolution in peer-reviewed Western literature.
Primary uses
- Age-related retinal aging support (Russian nutraceutical positioning)
- Adjunct in age-related macular degeneration (Russian clinical positioning)
- Adjunct in diabetic retinopathy (Russian clinical positioning)
Typical dosing
The amounts in circulation come from the maker's directions, not a controlled study, so no amount is printed here.
Regulatory status
Not FDA- or EMA-approved. Russian nutraceutical status only.
Status as of this entry's last review, October 4, 2026. Approvals, compounding rules and sport rules change; the regulatory tracker is checked more often.
What we checked
No paper indexed on PubMed names Visoluten and no sequence for it has been published that we could find. This section records what can be checked: the regulatory status on the date below, the related retinal preparations that are indexed, and every search we ran.
Identity, computed
| Sequence | Not established |
No sequence, formula or mass is given here because none has been published in a source we could find. This entry's original source, a 2008 Russian ophthalmology paper by Khavinson and colleagues, is not indexed on PubMed and could not be read.
Regulatory status, read October 4, 2026
Drugs@FDA: 0 records for “visoluten”. EMA medicines list: 0 records for “visoluten”. Run for semaglutide, the same queries return 6 and 5 records (and the registry search 84 trials), so a zero here is an absence, not a broken search. Not named on the WADA 2026 and 2027 Prohibited Lists. As a substance with no current approval for human therapeutic use, it falls under section S0 (non-approved substances), which is prohibited at all times; the lists were read on September 27, 2026.
What the maker or sellers claim
Claim, from Russian sellers: Visoluten supports the aging retina, including in macular degeneration and diabetic retinopathy. No indexed study tests Visoluten for any of these.
About retinal peptide preparations, not this product
The retinal preparation that does appear on PubMed is Retinalamin, a polypeptide extract of calf retina. In culture it stimulated division of retinal and pigment-epithelium cells, as did the synthetic tetrapeptide epitalon (Ala-Glu-Asp-Gly) at some concentrations (Khavinson et al., 2003). A 2013 study found epitalon and the dipeptide KE stimulated differentiation of embryonic retinal neurons and pigment-epithelium cells (Khavinson et al., 2013). Neither paper mentions Visoluten, and nothing we found says Visoluten contains Retinalamin, epitalon or KE.
What we looked for and did not find
No study naming Visoluten in any species, no published sequence, no pharmacokinetic data, no registry record and no dose from a controlled study.
| Source | Query | Results, October 4, 2026 | What it was |
|---|---|---|---|
| PubMed | visoluten | 0 | |
| PubMed | Khavinson retina | 17 | Retinalamin and epitalon retinal studies |
| PubMed | retina peptide bioregulator | 27 | Retinalamin, epitalon and unrelated retinal papers |
| NLM MeSH | visoluten | 0 | no record |
| ClinicalTrials.gov | visoluten | 0 | |
| Drugs@FDA (openFDA) | visoluten | 0 | |
| EMA medicines list | visoluten | 0 |
References
- [review] Khavinson VK, et al. "Peptide bioregulators in geriatric ophthalmology." Vestn Oftalmol, 2008;124:55-58 (Russian).
- [review] Anisimov VN, Khavinson VK. "Peptide bioregulation of aging: results and prospects." Biogerontology, 2010;11:139-149. PMID: 19830585.
- [pubmed] Khavinson VKh, et al. "Effects of peptides on proliferative activity of retinal and pigmented epithelial cells." Bull Exp Biol Med, 2003;135(6):597-9. PMID: 12937684.
- [pubmed] Khavinson VKh, et al. "Peptidegic regulation of differentiation of embryonic retinal cells." Bull Exp Biol Med, 2013;155(1):172-4. PMID: 23667897.
Related peptides
Guides & tools
This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.